Cutera Announces Limited Commercial Release of AviClear

AviClear is the first FDA-cleared laser for the long-term treatment of inflammatory acne vulgaris.

Cutera Inc., has announced a limited commercial release of AviClear for the UK & Ireland markets. This highly anticipated launch follows the successful rollout in the US and Canada.

“We are excited to be offering this ground-breaking AviClear treatment to physicians and patients in the UK & Ireland”, said Sam Keene, Regional Leader of UK & Ireland at Cutera. 

“Based on feedback from our early adopters, we are confident that patient demand and clinic installations will continue to grow over the next few months and that the affordability, efficacy, and durability of AviClear will establish it as the gold standard of care for acne sufferers.”

IMCAS Expert Panel Symposium

Cutera is hosting an AviClear symposium at IMCAS (1-3 Feb, 2024), with a global panel of leading key opinion leaders discussing AviClear clinical data and in-practice outcomes. Moderated by Dr David Goldberg and supported by Dr Tapan Patel, the panel will outline the trial results underpinning the FDA clearances, alongside their own in-clinic experiences.